TAR-210 [ERDAFITINIB], Mitomycin, Gemcitabin clinical trials

A phase 3, randomized, open-label, multicenter study evaluating the efficacy and safety of TAR-210 erdafitinib intravesical delivery system versus investigator’s choice of intravesical chemotherapy in participants with high-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations who had received intravesical Bacillus Calmette-Guérin (BCG)

This study looks at a new bladder cancer treatment called TAR-210 for people with high-risk, early-stage bladder cancer that hasn't spread to the muscle. It compares TAR-210 to standard chemotherapy to see which works best and is safest. You might be able to join if you've had a type of chemotherapy called BCG.